View Exam | PowerPak

1. Based on a recent meta-analysis, what was the estimated prevalence of tardive dyskinesia in first generation antipsychotic naïve patients who had received a second generation antipsychotic?

A. 7% B. 20% C. 23% D. 30%

2. What doses of deutetrabenazine were found to demonstrate clinical improvement in tardive dyskinesia as evidenced by a statistically significant reduction in AIMS score from baseline to Week 12 in the AIM-TD study?

A. 12 mg, 24 mg, and 36 mg per day B. 24 mg and 36 mg per day C. 12 mg and 24 mg per day D. 12 mg and 36 mg per day

3. According to the research criteria for tardive dyskinesia developed by Schooler and Kane, a diagnosis of “possible tardive dyskinesia” may result from the initial evaluation if which one of the following AIMS assessment findings are also present?

A. minimum of 6 months of antipsychotic treatment B. AIMS score of 1 or “minimal” in at least four body regions C. AIMS score of 2 or “mild” in at least one body region D. AIMS score of 3 or “moderate” in at least one body region

4. What doses of valbenazine were found to demonstrate clinical improvement in tardive dyskinesia as evidenced by a statistically significant reduction in AIMS score from baseline to Week 2, 4, and 6 in the KINECT 3 study?

A. 20 mg and 40 mg per day B. 40 mg and 60 mg per day C. 20 mg and 80 mg per day D. 40 mg and 80 mg per day

5. Which of the following best describes the mechanism of action of deutetrabenazine and valbenazine for the treatment of tardive dyskinesia?

A. non-selective VMAT1 and VMAT2 inhibition B. selective VMAT1 inhibition and reduced dopamine transport from cytosol to vesicles C. selective VMAT2 and dopamine receptor inhibition resulting in reduced dopamine transport D. selective VMAT2 inhibition and reduced dopamine transport from cytosol to vesicles

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Based on a recent meta-analysis, what was the estimated prevalence of tardive dyskinesia in first generation antipsychotic naïve patients who had received a second generation antipsychotic?

2. What doses of deutetrabenazine were found to demonstrate clinical improvement in tardive dyskinesia as evidenced by a statistically significant reduction in AIMS score from baseline to Week 12 in the AIM-TD study?

3. According to the research criteria for tardive dyskinesia developed by Schooler and Kane, a diagnosis of “possible tardive dyskinesia” may result from the initial evaluation if which one of the following AIMS assessment findings are also present?

4. What doses of valbenazine were found to demonstrate clinical improvement in tardive dyskinesia as evidenced by a statistically significant reduction in AIMS score from baseline to Week 2, 4, and 6 in the KINECT 3 study?

5. Which of the following best describes the mechanism of action of deutetrabenazine and valbenazine for the treatment of tardive dyskinesia?

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Based on a recent meta-analysis, what was the estimated prevalence of tardive dyskinesia in first generation antipsychotic naïve patients who had received a second generation antipsychotic?

2. What doses of deutetrabenazine were found to demonstrate clinical improvement in tardive dyskinesia as evidenced by a statistically significant reduction in AIMS score from baseline to Week 12 in the AIM-TD study?

3. According to the research criteria for tardive dyskinesia developed by Schooler and Kane, a diagnosis of “possible tardive dyskinesia” may result from the initial evaluation if which one of the following AIMS assessment findings are also present?

4. What doses of valbenazine were found to demonstrate clinical improvement in tardive dyskinesia as evidenced by a statistically significant reduction in AIMS score from baseline to Week 2, 4, and 6 in the KINECT 3 study?

5. Which of the following best describes the mechanism of action of deutetrabenazine and valbenazine for the treatment of tardive dyskinesia?

« Return to Activity

Customers who Purchased
this Activity also Purchased